Welcome to our dedicated page for Scisparc SEC filings (Ticker: SPRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SciSparc Ltd. filings document foreign private issuer disclosures for a clinical-stage pharmaceutical company with ordinary shares listed on Nasdaq. The record includes Form 6-K reports and Form 20-F references covering NeuroThera Labs patent and clinical-regulatory updates, cannabinoid-based drug programs, the MUSE endoscopic-system IP portfolio, and hemp seed oil-based product operations.
The company’s SEC materials also describe capital-structure and financing matters, including convertible promissory notes, warrants, resale registration statements, Form F-3 and Form S-8 incorporation, shareholder meeting approvals, reverse-share-split mechanics, Nasdaq continued-listing compliance, governance matters and risk-related disclosure categories.
SciSparc Ltd has announced a significant corporate action with a 1-for-21 reverse share split as reported in their Form 6-K filing dated June 28, 2025. This strategic move will consolidate every 21 existing shares into 1 new share.
Key filing details:
- Filing incorporates by reference into multiple registration statements, including Form F-3 (6 filings) and Form S-8 (3 filings)
- Document signed by Oz Adler, who serves as both Chief Executive Officer and Chief Financial Officer
- Company maintains its principal executive offices in Tel Aviv, Israel
- Confirms status as a Form 20-F filer for annual reports
The reverse split announcement suggests a potential strategic effort to meet minimum share price requirements for continued exchange listing or improve the stock's marketability to institutional investors.
SciSparc (Nasdaq: SPRC) filed Amendment No. 2 to its Form F-3 shelf registration, allowing the resale of up to 61,209,538 ordinary shares by existing investors.
The shares consist of (i) 53,617,021 shares issuable upon conversion of $4.2 million in convertible debentures and (ii) 7,592,517 shares issuable upon exercise of warrants. The debenture conversion price equals the lower of a fixed $0.4681 or 95 % of the 20-day VWAP, with a $0.0846 floor; warrants are exercisable at $0.5532. SciSparc will receive no proceeds from share resales, but could receive up to roughly $4.2 million in cash should all warrants be exercised.
The filing reiterates the company’s strategy of developing cannabinoid-based therapeutics (programs SCI-110 and SCI-210) and summarizes its pending merger with AutoMax Motors, an Israeli vehicle importer. The Merger Agreement has been amended four times (latest on 8 May 2025) and remains subject to shareholder approval.
Key investor considerations include: potential dilution from a share count materially larger than current float, a resale overhang that could pressure the $0.321 market price, and ongoing uncertainty surrounding the AutoMax merger. Risk factors highlight limited U.S. enforceability of judgments against the Israeli company and management, and the clinical-stage nature of operations with IFRS-based financials.